文献速递神经MRPETCT

基于影像组学鉴别复发性脑转移瘤与治疗效应:一项多机构先进影像对比研究

Radiomics-based Differentiation of Recurrent Brain Metastases from Treatment Effects: A Multi-Institutional Comparative Study with Advanced Imaging.
PubMed 文献 · Radiol Imaging Cancer · 2026-01-01

该多机构回顾性研究纳入242例脑转移瘤治疗后患者,比较影像组学、先进影像模态与RANO-BM标准鉴别肿瘤复发与治疗效应的能力。影像组学在强化病灶、水肿和坏死核心亚分区中准确率分别为70.6%、71.4%和72.0%,对比子集中影像组学准确率76.5%优于RANO-BM的39.2%(P < .001)。

要点

  • 影像组学鉴别肿瘤复发与治疗效应准确率76.5%,优于RANO-BM的39.2%(P < .001)。
  • 基于T2强化病灶、FLAIR水肿和FLAIR坏死核心的模型准确率分别为70.6%、71.4%、72.0%。
  • 各研究机构间强化病灶、水肿和坏死亚分区平均准确率分别为68.9%、67.9%、70.7%。

核心结论

  • 影像组学在鉴别肿瘤复发与治疗效应方面优于RANO-BM标准和先进影像模态,且在病灶各亚分区中均表现出更高的准确率。

研究设计与样本

  • 多机构回顾性研究,纳入三个机构2001年1月至2023年3月242例患者(平均年龄59岁±11.5,女性114例)的治疗后MRI数据,参考标准为组织病理学或临床及影像病程。

诊断标准与关键数值

  • 包含强化病灶T2加权MRI特征的模型准确率为70.6%。
  • 包含水肿FLAIR特征的模型准确率为71.4%。
  • 包含坏死核心FLAIR特征的模型准确率为72.0%。
  • 对比子集中影像组学准确率76.5% vs RANO-BM准确率39.2%,P < .001。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To compare the ability of radiomics, advanced imaging modalities, and Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria to distinguish tumor recurrence from treatment effects in patients with brain metastasis. Materials and Methods Posttreatment MRI (gadolinium-enhanced T1-weighted, T2-weighted, fluid-attenuated inversion recovery [FLAIR]) data of patients from three institutions, obtained between January 2001 and March 2023, were retrospectively analyzed. Reference standards were established by histopathology or according to clinical and imaging courses. Following preprocessing and segmenting tumors into subcompartments of enhancing lesion, edema, or necrotic core, 1104 radiomic features were extracted, and classification was conducted using random forest models. A comparative assessment with advanced imaging and RANO-BM was performed using a subset of studies with available modalities (dynamic susceptibility contrast MRI, fluorine 18 [18F] fluorodeoxyglucose [FDG] PET/MRI, 18F-FDG PET/CT, and longitudinal gadolinium-enhanced T1-weighted MRI). Statistical analyses were performed using the McNemar test. Results The study included data from 242 patients (mean age, 59 years ± 11.5; 114 female patients). Models including T2-weighted MRI features from the enhancing lesion, FLAIR features from edema, and FLAIR features from necrotic core subcompartments yielded accuracies of 70.6%, 71.4%, and 72.0%, respectively. The average accuracies for the enhancing lesion, edema, and necrotic subcompartments across different study sites were 68.9%, 67.9%, and 70.7%, respectively. In comparative subset analyses, radiomics outperformed other techniques in distinguishing tumor recurrence from treatment effects (eg, 76.5% vs 39.2% accuracy using RANO-BM, P < .001). Conclusion Radiomics outperformed RANO-BM criteria and advanced imaging modalities in differentiating tumor recurrence from treatment effects, with consistently higher accuracies across lesion subcompartments. Keywords: Brain Metastases, Treatment Effects, Radiomics, RANO-BM, Advanced Imaging Supplemental material is available for this article. © RSNA, 2026.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Um H, Ismail M, Hill VB, et al. Radiomics-based Differentiation of Recurrent Brain Metastases from Treatment Effects: A Multi-Institutional Comparative Study with Advanced Imaging. Radiol Imaging Cancer. 2026. PMID: 41995469. doi:10.1148/rycan.250435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。